BRPI0921835A8 - Formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento. - Google Patents

Formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento.

Info

Publication number
BRPI0921835A8
BRPI0921835A8 BRPI0921835A BRPI0921835A BRPI0921835A8 BR PI0921835 A8 BRPI0921835 A8 BR PI0921835A8 BR PI0921835 A BRPI0921835 A BR PI0921835A BR PI0921835 A BRPI0921835 A BR PI0921835A BR PI0921835 A8 BRPI0921835 A8 BR PI0921835A8
Authority
BR
Brazil
Prior art keywords
formulation
animal
mammary gland
administrate
teta
Prior art date
Application number
BRPI0921835A
Other languages
English (en)
Inventor
Frederick Leech Wayne
Risto Petrovski Kiro
Al Alawi Fadil
Original Assignee
Mastitis Res Centre Limited
Bayer New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mastitis Res Centre Limited, Bayer New Zealand Ltd filed Critical Mastitis Res Centre Limited
Publication of BRPI0921835A2 publication Critical patent/BRPI0921835A2/pt
Publication of BRPI0921835A8 publication Critical patent/BRPI0921835A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAÇÃO ÚNICA PARA ADMINISTRAR AO CANAL DE TETA DA GLÂNDULA MAMÁRIA DE UM ANIMAL E USO DA FORMULAÇÃO NA MANUFATURA E UM MEDICAMENTO. Refere-se a presente invenção a uma formulação para administração ao canal de teta da glândula mamária de um animal, sendo que a formulação inclui: um material de barreira física, caracterizado pelo fato de a formulação incluir antibiótico suficiente em relação ao material de barreira física de forma tal que a formulação é configurada para desintegrar durante um período de tempo depois para desintegrar-se durante um período de tempo depois da administração ao canal de teta.
BRPI0921835A 2008-11-28 2009-11-25 Formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento. BRPI0921835A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ57329708 2008-11-28
PCT/NZ2009/000255 WO2010062194A1 (en) 2008-11-28 2009-11-25 Animal treatment formulation and methods of use

Publications (2)

Publication Number Publication Date
BRPI0921835A2 BRPI0921835A2 (pt) 2017-10-24
BRPI0921835A8 true BRPI0921835A8 (pt) 2017-12-12

Family

ID=42225884

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921835A BRPI0921835A8 (pt) 2008-11-28 2009-11-25 Formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento.

Country Status (6)

Country Link
US (1) US20120022038A1 (pt)
EP (1) EP2376196A4 (pt)
AU (1) AU2009320504A1 (pt)
BR (1) BRPI0921835A8 (pt)
WO (1) WO2010062194A1 (pt)
ZA (1) ZA201104722B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025855A2 (pt) * 2017-06-09 2020-07-14 Zoetis Broomhill Ip Limited composição veterinária intramamária
US20240382647A1 (en) * 2023-05-18 2024-11-21 Filid Tecnologia Farmacêutica Ltda (ME) Method for Preparing an Intramammary Teat Sealing Composition and Sealing Composition Obtained By Such Process

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2273441B (en) 1992-12-08 1997-01-08 Bimeda Res Dev Ltd Veterinary compositions for treating mastitis
EP0971690B2 (en) * 1996-12-18 2015-04-01 Bimeda Research & Development Limited Antiinfective free intramammary veterinary composition
DE19654826A1 (de) 1996-12-23 1998-06-25 Veyx Pharma Gmbh Veterinärarzneiliche Darreichungsform zur Anwendung von biologisch aktiven Wirkstoffen in engen Körperhöhlen und Verfahren zu ihrer Herstellung
US20030060414A1 (en) * 2001-09-10 2003-03-27 Mchardy Nicholas Bio-security system
US20040197422A1 (en) * 2002-12-20 2004-10-07 Pfizer Inc Veterinary compositions for treating mastitis
US20050191270A1 (en) 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
MX2009003924A (es) 2006-10-10 2009-11-10 Wisconsin Alumni Res Found Formulacion selladora intra-mamaria para el pezon y metodo para utilizar la misma para reducir o eliminar los defectos visuales en quesos añejos.
NZ571347A (en) 2008-09-17 2010-04-30 Mastitis Res Ct Ltd Anti-infective formulation and methods of use

Also Published As

Publication number Publication date
BRPI0921835A2 (pt) 2017-10-24
US20120022038A1 (en) 2012-01-26
EP2376196A4 (en) 2012-05-30
ZA201104722B (en) 2012-12-27
EP2376196A1 (en) 2011-10-19
AU2009320504A1 (en) 2011-07-07
WO2010062194A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CR11470A (es) Compuestos organicos
BR112012010083B8 (pt) Composição farmacêutica tópica de liberação sustentada e uso relacionado
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
PE20061009A1 (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparacion, y composiciones farmaceuticas que la contienen
MX2010005346A (es) Composiciones farmaceuticas.
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112012024885A2 (pt) composições bioadesivas de anestésicos locais
AR081670A1 (es) Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
CY1120435T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν κρυσταλλικες μορφες του μονοενυδρου υδροχλωρικου (r)-7-χλωρο-ν-(κινουκλιδινο-3-υλο) βενζο(β)θειοφαινο-2-καρβοξαμιδιου
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112012024999A2 (pt) combinação e uso
CR10407A (es) Formulacion de medicamento liquida.
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BRPI0921835A8 (pt) Formulação única para administrar ao canal de teta da glândula mamária de um animal e uso da formulação na manufatura de um medicamento.
AR077915A1 (es) Forma cristalina de pemirolast
BR112015022398A8 (pt) comprimido de ondansetrona e preparação farmacêutica embalada
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER NEW ZEALAND LIMITED (NZ)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]